Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1362-1368

  Tian, Wenxia ^a   Li, Bing ^a   Zhang, Xiwen ^a   Dang, Weiqi ^a   Wang, Xiaofei ^a   Tang, Hao ^a   Wang, Lin ^a   Cao, Hong ^a   Chen, Tingmei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Antimicrobial peptide; Matrix matalloproteinase 9; Porcine cathelicidin; Signal transducers and activators of transcription 3; siRNA

Indexed keywords

LIPOFECTAMINE; PR 39; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENE REPRESSION; GENE SILENCING; GENE TRANSLOCATION; IN VITRO STUDY; METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; STAT3 GENE;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENE SILENCING; GENE TRANSFER TECHNIQUES; MICE; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 84866467316     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1911     Document Type: Article

References (33)

1. Yang SY: Sniper the hyperplasia of mammary glands and escort for the women health. Med People: 34-35, 2007.
2. Jun JY, Griffith JW, Bruggeman R, et al: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 107: 33-40, 2008.
3. Garcia R, Yu CL, Hudnall A, et al: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8: 1267-1276, 1997.
4. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
5. Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251: 199-210, 2007.
6. Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749, 2002.
7. Chiu WT, Lee HT, Huang FJ, et al: Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res 71: 4932-4943, 2011.
8. Blaskovich MA, Sun J, Cantor A, et al: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279, 2003.
9. Leong PL, Andrews GA, Johnson DE, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100: 4138-4143, 2003.
10. Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648, 1996.
11. Mora LB, Buettner R, Seigne J, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
12. Nakajima K, Yamanaka Y, Nakae K, et al: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15: 3651-3658, 1996.
13. Ni Z, Lou W, Leman ES, et al: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228, 2000.
14. de Fougerolles A, Vornlocher HP, Maraganore J and Liberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453, 2007.
15. Akhtar S and Benter I: Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 164-182, 2007.
16. Bumcrot D, Manoharan M, Koteliansky V and Sah DW: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719, 2006.
17. Nakamura Y, Kogure K, Futaki S and Harashima H: Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 119: 360-367, 2007.
18. Agerberth B, Lee JY, Bergman T, et al: Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem 202: 849-854, 1991.
19. Boman HG, Agerberth B and Boman A: Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun 61: 2978-2984, 1993.
20. Storici P and Zanetti M: A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39. Biochem Biophys Res Commun 196: 1058-1065, 1993.
21. Shi J, Ross CR, Leto TL and Blecha F: PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47phox. Proc Nat Acad Sci USA 93: 6014-6018, 1996.
22. Chan YR and Gallo RL: PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas). J Biol Chem 273: 28978-28985, 1998.
23. Gao Y, Lecker S, Post MJ, et al: Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 106: 439-448, 2000.
24. Alshamsan A, Hamdy S, Samuel J, et al: The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31: 1420-1428, 2010.
25. Ye Y, Yin DT, Chen L, et al: Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis. PLoS One 5: e13406, 2010.
26. Ohtake T, Fujimoto Y, Ikuta K, et al: Proline-rich antimicrobial peptide, PR39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br J Cancer 81: 393-403, 1999.
27. Ohki EC, Tilkins ML, Ciccarone VC and Price PJ: Improving the transfection efficiency of post-mitotic neurons. J Neurosci Methods 112: 95-99, 2001.
28. Wang YH, Chen CP, Chan MH, et al: Arginine-rich intracellular delivery peptides noncovalently transport protein into living cells. Biochem Biophys Res Commun 346: 758-767, 2006.
29. Wang YH, Hou YW and Lee HJ: An intracellular delivery method for siRNA by an arginine-rich peptide. J Biochem Biophys Methods 70: 579-586, 2007.
30. Kim SW, Kim NY, Choi YB, et al: RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 143: 335-343, 2010.
31. Zhang X, Oglecka K, Sandgren S, et al: Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochim Biophys Acta 1798: 2201-2208, 2010.
32. Hoskin DW and Ramamoorthy A: Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778: 357-375, 2008.
33. Veldhoen S, Laufer SD, Trampe A and Restle T: Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 34: 6561-6573, 2006.